-The Times of India India's intellectual property (IP) law has been hailed as one of the most progressive for safeguarding public interest, and several nations like Argentina, the Philippines and Brazil are looking to learn from it. Senior advocate and former UN special rapporteur on the right to health Anand Grover talks to Rema Nagarajan about the pressure the country is facing to change its IP laws, primarily from the US. *...

-AP American scientist Joshua Apte travels in an autorickshaw to present alarming findings for anyone who spends time on or near the roads in this city of 25 million. The autorickshaw lurched through New Delhi's commuter-clogged streets with an American scientist and several air pollution monitors in the back seat. Car horns blared. A scrappy scooter buzzed by belching black smoke from its tailpipe. One of the monitors spiked. Joshua Apte has alarming...

-The Hindu Business Line Report lauds rapid progress in health indicators, especially in Maharashtra India is making rapid strides in overcoming the problem of malnutrition, with the number of stunted children under the age of five declining by over 10 million, says a ‘Global Nutrition Report'. The "first-ever comprehensive narrative on global health and country-level progress toward reducing malnutrition", brought out by a consortium of nations, organisations, researchers, and academics, covers each of...

-Economic and Political Weekly The current regime seeks to reform labour laws with the understanding that these reforms will improve industrial growth and expand the possibilities of enterprise. However, there is already ample evidence from within India that this obsession with reforming labour law, particularly in the way the government has done it till now, will not take us any closer in creating more jobs or a healthy industrial sector. These...

-Down to Earth Pharma company's strategy of different prices for different countries to affect quality treatment of 185 million people infected with Hepatitis C worldwide Health activists and agencies on Tuesday criticised leading pharmaceutical company Bristol-Myers Squibb (BMS)'s commercial strategy to sell new Hepatitis C medicine Daclatasvir, stating it would exclude a large number of patients who cannot afford expensive treatment. BMS had announced that it would create a tiered pricing strategy for...